

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED**

**銘源醫療發展有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0233)**

### **CO-OPERATION AGREEMENT WITH CHINESE NATIONAL HUMAN GENOME CENTER IN SHANGHAI AND SHANGHAI BIOCHIP CO., LTD. ON INFLUENZA A VIRUS GENOTYPING DETECTION KITS**

The Board is pleased to announce that the Company had entered into a Co-operation Agreement with CHGC and SBC on 10 June 2009 for the joint development and production of diagnostic kits for detecting Influenza A viruses.

The board of directors (the “Board”) of Mingyuan Medicare Development Company Limited (the “Company”) is pleased to announce that the Company had entered into a milestone co-operation agreement (the “Co-operation Agreement”) with Chinese National Human Genome Center in Shanghai (“CHGC”) and Shanghai Biochip Co., Ltd. (“SBC”) on 10 June 2009 for the joint development and production of advanced diagnostic kits for detecting Influenza A viruses.

Under the Co-operation Agreement, CHGC and SBC had successfully developed two advanced diagnostic kits for detecting Influenza A viruses, the Influenza A Virus Genotyping Detection Kit (RNA FQ-PCR) and the Influenza A Virus Genotyping Detection Kit (Sequencing) (collectively the “Kits”) and SHMY Healthdigit Biochips Company Limited (“Healthdigit Biochips”), a wholly owned subsidiary of the Company, will be responsible for the registration of the Kits with the State Food and Drug Administration in China. Healthdigit Biochips will share jointly with CHGC and SBC for the ownership of all intellectual property rights relating to the Kits. In addition to development of the Kits, all parties to the Co-operation Agreement has agreed to establish a uniquely dynamic technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases on demand basis.

Influenza A viruses (including the recent outbreak of Influenza A(H1N1) virus) is a highly infectious disease which has long been regarded as a major health hazard to human. The outbreak of Influenza A(H1N1) virus had prompted the World Health Organization to raise the influenza pandemic alert level from Phase 4 to Phase 5, just one below the highest pandemic phase. It is known that early detection of Influenza A(H1N1) virus is an effective measure to better prevent the spread of the infectious disease and to improve the chance of recovery for patients.

Established in 1998, CHGC is a national research center for fulfilling the national scientific projects of human genome research and its application and development for China. CHGC was founded by many established institutes from the related biotech fields in Shanghai and the relevant government agencies including the Chinese Ministry of Science and Technology, Shanghai Municipal Government and Chinese Academy of Sciences (“CAS”).

Founded in 2001, SBC is one of the largest biotech companies in China and is also the National Engineering Center for biochip design and engineering in Shanghai. Facilitated with advanced biotech platforms and labs and operated by strong teams for research, services, marketing and sales, SBC provides a series of biochips and related technical services, proprietary drug targets and relevant diagnostic products. SBC is funded by the Chinese government and was founded by eleven shareholders including the Shanghai Institute for Biological Sciences of CAS and other shareholders consisting of all top academic universities, research institutes, hospitals, and leading biotech companies.

By order of the Board  
**Mingyuan Medicare Development Company Limited**  
銘源醫療發展有限公司\*  
**Kenny Poon**  
*Company Secretary*

Hong Kong, 11 June 2009

*As at the date of this announcement, the executive directors are Mr. Yao Yuan (Executive Chairman), Mr. Chien Hoe Yong, Henry (CEO), Mr. Iu Chung, Mr. Hu Jun, and Mr. Yu Ti Jun; non-executive directors are Mr. Yang Zhen Hua and Mr. Ma Yong Wei; the independent non-executive directors are Dr. Lam Lee G., Mr. Hu Jin Hua and Mr. Lee Sze Ho, Henry.*

\* *For identification purposes only*